AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03225027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recognition task
Description: Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
Study NCT03225027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detection task
Description: Participants indicate every time they heard a given sound in order to verify their audition level.
Study NCT03225027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAPE-42
Description: This questionnaire allows evaluating the nature of psychotic experiences.
Study NCT04921540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ingrown toenails with only surgery
Description: Removal of the ingrown lateral part of the toenail with directed Healing pad
Study NCT03822806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise in addition to Patching
Description: Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
Study NCT02188459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
Study NCT02188459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
Study NCT03974672 — intervention group
Intervention type: PROCEDURE
Intervention: Re-laparotomy
Study NCT02359214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
Study NCT04084262 — intervention group
Intervention type: DEVICE
Intervention: Intramedullary Nail
Description: Subjects undergo a Lapidus Arthrodesis procedure combined with a supinating reduction technique to create a multi-plane correction of hallux valgus
Study NCT03305172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Giving different structures of long term (36 weeks) financial incentives to increase physical activity
Study NCT00470483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment during 8 weeks
Description: comparator
Study NCT00470483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine treatment during 8 weeks
Description: treatment drug
Study NCT01828021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: Anti-HER2 monoclonal antibody
Study NCT02442557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injection
Study NCT02359214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100% Lactose tablet daily over 8 weeks (56 days).
Study NCT02442557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: intravenous injection
Study NCT03535636 — intervention group
Intervention type: OTHER
Intervention: Polysomnography
Description: Sleep architecture will be assessed by polysomnography
Study NCT03582813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed care
Description: Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
Study NCT03582813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
Study NCT01947114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT01947114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT01947114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT02364648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Mitochondria targeted antioxidant
Study NCT02364648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00135278 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CSF Drainage
Description: See Detailed Description
Study NCT00135278 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No CSF Drainage
Description: See Detailed Description
Study NCT02290548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: High flow nasal cannula used in postextubation patients
Study NCT02290548 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: high flow nasal cannula
Description: High flow nasal cannula used in postextubation patients
Study NCT04794660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HPV DNA Test
Description: Screening for HPV using a HPV DNA test
Study NCT04263740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.
Study NCT04263740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Physical therapy
Description: Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
Study NCT04263740 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional Physical therapy
Description: Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
Study NCT03225027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trait Emotional Intelligence Questionnaire
Description: To evaluate their emotional intelligence.
Study NCT02692599 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control live attenuated mumps vaccine
Description: The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
Study NCT02457923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone counselling
Description: i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
Study NCT01735643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interactive videogame Wii Fit Plus
Description: Use of the interactive videogame Wii Fit Plus für 12 weeks.
Study NCT01735643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: waiting
Description: waiting for 12 weeks
Study NCT04794660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VIA triage test
Description: VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer
Study NCT04794660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment by ablative treatment
Description: Cryotherapy or Thermal Ablation are performed on the cervix.
Study NCT04794660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy
Description: Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
Study NCT03571074 — intervention group
Intervention type: OTHER
Intervention: Oxygenation
Description: Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
Study NCT01066247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride; Midazolam
Description: intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
Study NCT01066247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
Study NCT02260479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preheated
Description: Skin disinfection solution is preheated in a warming cupboard
Study NCT05884047 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Glasses
Description: In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video.
Study NCT01603459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection.
Study NCT00196716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabrazyme (agalsidase beta)
Description: 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
Study NCT00916747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib, Zoledronic Acid, and Pravastatin
Description: Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily.
Study NCT03644745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VM @ Home Usability
Description: Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
Study NCT02525094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI9929
Description: Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
Study NCT02525094 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
Study NCT00663299 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular Embolization Device
Description: The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
Study NCT04051554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular and Proprioceptive Training
Description: Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
Study NCT04051554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Running, Sprinting, Agility training and Dynamic stretching for five weeks
Study NCT01804569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: modernly developed moxibustion treatment device with safe cover on top of it.
Study NCT02177513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Placebo
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
Study NCT02177513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cannabis + Placebo
Description: Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
Study NCT02177513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Inhaled Cannabis
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
Study NCT02177513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Smoked Cannabis
Description: Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
Study NCT02177513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6.9% cannabis oral
Description: Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
Study NCT03002454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc MDP Injection:neutron-bombardment
Description: Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
Study NCT03256747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
Study NCT03256747 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NMES-placebo
Description: NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
Study NCT02789410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine is administered as part of spinal anesthesia for post-operative pain relief.
Study NCT02789410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
Study NCT02335099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: ticagrelor 90 mg twice a day for 6 months
Study NCT02335099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill twice a day for 6 months
Study NCT00075582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Some patients may undergo second-look surgery
Study NCT00075582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given IV
Study NCT05108597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
Study NCT03033342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral single doses of MRX-4
Description: Oral single escalating doses of MRX-4
Study NCT03033342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral multiple doses of MRX-4
Description: Multiple ascending doses of MRX-4 given twice daily for 10 days
Study NCT03033342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-4 co-administered with omeprazole
Description: MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
Study NCT03033342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral single doses of placebo
Description: Single doses of placebo to match MRX-4
Study NCT03033342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral multiple doses of placebo
Description: Oral placebo given twice daily for 10 days to match the oral MRX-4
Study NCT03033342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo co-administered with omeprazole
Description: Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
Study NCT02303899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: infusion drug
Study NCT02303899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: oral drug
Study NCT03984630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Intervention
Description: Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
Study NCT01813123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealTeen
Description: A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
Study NCT02609685 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Surveillance
Description: Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
Study NCT04376827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Participants will receive guselkumab Dose 1 via IV administration.
Study NCT04376827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
Study NCT04376827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Participants will receive guselkumab Dose 2 via SC route.
Study NCT04376827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care treatment
Description: Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.